Abstract
Interleukin-6 (IL-6), a central proinflammatory cytokine, may be involved in both development and progression of many human malignancies. Therefore, we aimed to evaluate any associations of IL-6 gene polymorphisms with susceptibility and overall survival of osteosarcoma in a Chinese population. A total of 412 subjects, including 206 patients with osteosarcoma and 206 healthy controls, were recruited and were assessed by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) in this study. Significant differences of genotype distribution were observed between osteosarcoma cases and controls at the IL-6 −174 G/C genotypes. Compared with the homozygote GG, the heterozygous GC genotype was associated with significantly increased risk for osteosarcoma (odds ratio [OR] = 1.58, 95 % confidence interval [CI] = 1.13–3.05, p = 0.028); the CC genotype was associated with increased risk for osteosarcoma (OR = 1.57, 95 % CI = 1.21–3.26, p = 0.022). Moreover, the genotype CC of IL-6 −174 G/C carried a higher risk of osteosarcoma metastasis and later Enneking stages, compared with the GG genotype. The IL-6 −174 G/C genotype was associated with risk for development and metastasis of osteosarcoma in Chinese Han population.
Similar content being viewed by others
References
Kramárová E, Stiller CA. The international classification of childhood cancer. Int J Cancer. 1996;68:759–65.
Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–41.
Fletcher CD, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. 2002. Iarc.
Bai SB, Chen HX, Bao YX, Luo X, Zhong JJ. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma. APJCP. 2013;14:3677–80.
Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075–85.
Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99.
Lukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn. 2007;117:247–51.
Crohns M et al. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy—association of interleukin-8 and VEGF with survival. Cytokine. 2010;50:30–6.
Culig Z et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95:497–505.
Giannitrapani L et al. Genetic association of interleukin-6 polymorphism (−174G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol. 2013;19:2449–55.
Hefler LA et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003;63:3066–8.
Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B. Association of interleukin-6 (−174G > C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin Immunol. 2008;128:199–204.
Yang M, Li C, Li M. Association of interleukin-6 (−174 G/C) polymorphism with the prostate cancer risk: a meta-analysis. Biomed Rep. 2014;2:637–43.
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activatedreceptor gamma with colorectal cancer. Cancer Res. 2003;63:3560–6.
Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, et al. Strong association of interleukin-6 −174 G > C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers. 2006;21:246–50.
Shi WJ, Liu H, Wu D, Tang ZH, Shen YC, Guo L. Stratification analysis and case–control study of relationships between interleukin-6 gene polymorphisms and cervical cancer risk in a Chinese population. Asian Pac J CancerPrev. 2014;15:7357–62.
Boerman I, Selvarajah GT, Nielen M, Kirpensteijn J. Prognostic factors in canine appendicular osteosarcoma—a meta-analysis. BMC Vet Res. 2012;8:56.
Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012;72:1865–77.
Teng JW, Yang ZM, Li J, Xu B. Predictive role of glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy. Pak J Med Sci. 2013;29:1182–6.
Zarogoulidis P et al. Interleukin-6 cytokine: a multifunctional glycoprotein for cancer. Immunol Res. 2013;9(62):16535.
Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46(7):1223–31.
Gomes M, Coelho A, Araújo A, Azevedo A, Teixeira AL, Catarino R, et al. IL-6 polymorphism in non-small cell lung cancer: a prognostic value? Tumour Biol. 2015;36:3679–84.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Qi, Y., Zhao, C., Li, H. et al. Genetic variations in interleukin-6 polymorphism and the association with susceptibility and overall survival of osteosarcoma. Tumor Biol. 37, 9807–9811 (2016). https://doi.org/10.1007/s13277-016-4876-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-016-4876-6